MicroRNA: A new therapeutic strategy for cardiovascular diseases

Samanta, Saheli; Balasubramanian, Sathyamoorthy; Rajasingh, Sheeja; Patel, Urmi; Dhanasekaran, Anuradha; Dawn, Buddhadeb; Rajasingh, Johnson

doi:10.1016/j.tcm.2016.02.004

Cited by 110 publications

(56 citation statements)

References 105 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miRNA treatment options focus on the specific artificial elevation or suppression of selected miRNA levels. Detailed explanations on the mode of function of the diverse approaches on how to alter miRNA levels can be found elsewhere [17,135,136]. Briefly, a specific elevation of target miRNAs can be achieved by miRmimics [137], while miRNA suppression can be obtained by anti-miRNA antisense oligomers -so-called antagomiRs [138,139], sponges [140][141][142], masking [143] and erasers [139].…”

Section: Mirnas -Therapeutic Applicationmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

107

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirnas -Therapeutic Applicationmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

107

View full text Add to dashboard Cite

show abstract

“…Many miRNA profiling studies in plasma or extracellular carriers have found significantly altered miRNAs in a wide-variety of diseases, many of which are now being considered as potential biomarkers for different aspects of CVD, see reviews (Joladarashi, Thandavarayan, Babu, & Krishnamurthy, 2014; Samanta, et al, 2016). At the time of this review, there are currently 159 clinical trials investigating miRNA biomarkers in diseases, including breast cancer (ClinicalTrials.gov identifier: NCT01612871), acute myeloid leukemia (NCT01057199), and periodontal disease (NCT02069574).…”

Section: Current Development Of Mirna Therapeutics That May Impactmentioning

confidence: 99%

HDL and microRNA therapeutics in cardiovascular disease

Michell

Vickers

2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

microRNAs (miRNA) are small non-coding RNAs (sRNA) that post-transcriptionally regulate gene (mRNA) expression and are implicated in many biological processes and diseases. Many miRNAs have been reported to be altered in cardiovascular disease (CVD); both cellular and extracellular miRNA levels are affected by hypercholesterolemia and atherosclerosis. We and other groups have reported that lipoproteins transport miRNAs in circulation and these lipoprotein signatures are significantly altered in hypercholesterolemia and coronary artery disease (CAD). Extracellular miRNAs are a new class of potential biomarkers for CVD; however, they may also be new drug targets as high-density lipoproteins (HDL) transfer functional miRNAs to recipient cells in an endocrine-like form of intercellular communication that likely suppresses vascular inflammation. Recently, RNA-based drugs have emerged as the next frontier in drug therapy, and there are many miRNA inhibitors and mimics in clinical development. Here, we discuss specific miRNA drug targets and how their manipulation may impact CVD. We also address the potential for manipulating HDL-miRNA levels to treat CVD and the use of HDL as a delivery vehicle for RNA and chemical drugs. Finally, we outline the current and future challenges for HDL and miRNA-based therapeutics for the prevention and treatment of CVD.

show abstract

“…The expression pattern of miRNAs can provide information about the pathophysiological processes underlying HF, such as myocardial fibrosis and hypertrophy [5, 15, 16]. For example, Duisters et al [17] showed that both miR-133 and miR-30 directly downregulate connective tissue growth factor, which is associated with myocardial fibrosis [8, 17].…”

Section: Discussionmentioning

confidence: 99%

Association of miR-197-5p, a Circulating Biomarker for Heart Failure, with Myocardial Fibrosis and Adverse Cardiovascular Events among Patients with Stage C or D Heart Failure

Liu

Zheng²,

Dong

et al. 2018

Cardiology

View full text Add to dashboard Cite

Objective: The aim of this study was to identify heart failure (HF)-specific circulating micro-RNAs (miRNA), and examine whether the selected miRNAs correlate with myocardial fibrosis and are reflective of the incidence of adverse cardiovascular events in patients with stage C or D HF. Methods: Circulating miRNAs which were expressed in end-stage HF patients and matched healthy controls were detected by microarray analysis and validated by quantitative real-time polymerase chain reaction. Multivariate Cox regression analysis was performed to determine whether the selected circulating miRNAs could be prognostic factors in HF patients. Results: In a cohort of 7 healthy controls and 9 patients with stage C or D HF, 7 miRNAs were differentially expressed. These miRNAs were further investigated in a second cohort of 80 patients with stage C or D HF and 30 healthy controls. Only miR-197-5P correlated with fibrosis as seen in cardiac magnetic resonance imaging in patients under the age of 50 years with stage C or D HF (r = 0.42, p = 0.008). Multivariate analyses revealed that miR-197-5P was also a risk factor for composite endpoint events in patients under the age of 50 years with stage C or D HF. Conclusion: miR-197-5P is a circulation miRNA that correlates with MF and adverse cardiac events in HF patients under the age of 50 years.

show abstract

MicroRNA: A new therapeutic strategy for cardiovascular diseases

Cited by 110 publications

References 105 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

HDL and microRNA therapeutics in cardiovascular disease

Association of miR-197-5p, a Circulating Biomarker for Heart Failure, with Myocardial Fibrosis and Adverse Cardiovascular Events among Patients with Stage C or D Heart Failure

Contact Info

Product

Resources

About